Canagliflozin (Invokana), a novel oral agent for type-2 diabetes

P and T

Volumn 38, Issue 11, 2013, Pages

  Sarnoski Brocavich, Sheila ^a   Hilas, Olga ^b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; GLUCURONOSYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENYTOIN; PLACEBO; RIFAMPICIN; RITONAVIR; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DIABETIC OBESITY; DIET; DRUG BIOAVAILABILITY; DRUG COST; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FUNGAL GENITAL INFECTION; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; LIFESTYLE MODIFICATION; MENTAL STRESS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSMOTIC DIURESIS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYURIA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84887854452     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Number (in millions) of civilian, noninstitutionalized persons with diagnosed diabetes, United States, 1980-2011. CDC Data Sheet. Available at: www.cdc.gov. Accessed June 24, 2013.
2. Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet, 2011. Available at: www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed June 20, 2013.
3. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the U.S. adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29.
4. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1);S67-S74.
5. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a U.S. adult population: Findings from the National Health and Nutrition Examination survey, 1999-2006. Obes Surg 2011;21:351-355.
6. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
7. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1);S11-S66
8. Stark Casagrande S, Fradkin JE, Saydah SH. The prevalence of meeting A1c, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care, February 15, 2013 (online).
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: Patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
10. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive diabetes management algorithm. Endocr Pract 2013;19(2):327-336.
11. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel c-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 Inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53: 6355-6360.
12. Valentine V. The role of the kidney and sodium-glucose co-transporter-2 inhibition in diabetes management. Clin Diabetes 2012:30;151-155.
13. FDA approves Invokana to treat type 2 diabetes: First in a new class of diabetes drugs. March 29, 2013. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/Ucm345848.htm. Accessed May 20, 2013.
14. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-385.
15. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-327.
16. Idris I, Donnelly R. Sodium-glucose cotransporter-2 inhibitors: An emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11(2):79-88.
17. Invokana (canagliflozin), prescribing information. Titusville, N.J.: Janssen; March 2013.
18. AMCP Dossier Invokana (canagliflozin). Titusville, N.J.: Janssen MedInfo; April 15, 2013.
19. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:378-382.
20. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotranstporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35:1232-1238.
21. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care 2013;36(19):2508-2515.
22. Red Book Online 2013. Available at: www.micromedexsolutions.com. Accessed July 1, 2013.